Supervisory Board

Dr. Pär Johansson is the chairman of the Advisory Board and of the Supervisory Board. After completing his certificate of secondary education, he served as a first-aid medic for the German Red Cross. He then studied law at universities in Bonn, Cologne and Paris. His training also included a stage in a law firm in San Francisco. In 1994, Dr. Johansson completed his PhD at the University of Cologne.

After joining the law firm Heuking Kühn Lüer Wojtek in 1995, Dr. Johansson became a partner in 1999. His areas of expertise include corporate law and mergers and acquisitions. Dr. Johansson advises national and international clients on corporate law, acquisitions and restructuring activities. Dr. Johansson has published work related to corporate law and inheritance law. For more than ten years, he served as one of the firm’s managing partners and assumed e.g. the role of the chief financial officer of the law firm.

Dr. Petra Danielsohn-Weil has over 30 years of experience in the pharmaceutical industry at Warner-Lambert and Pfizer, in both strategic and operational roles at global, regional and local levels. Dr. Danielsohn-Weil currently serves as an Advisor for Innovaacom. She studied Chemistry, Biology and Educational Sciences in Würzburg, Berlin and Münster, Germany, and holds a PhD in Biology from the University of Münster.

Dr. Max Schwesig has more than 20 years of leadership experience in digital transformation, business development, pharmacy software and pharmaceutical retail operations across Europe. He currently serves as Chief Digital Officer Employee Experience & Corporate Applications at PHOENIX group SE, where he is responsible for the end-to-end management and delivery of mission critical services and workplace automation initiatives across 29 countries.

Before taking on his current role in 2023, Dr. Schwesig was Managing Director at the pharmacy software company ADG Apotheken Dienstleistungsgesellschaft mbH, where he led international subsidiaries across Central, Eastern and Southeastern Europe. Earlier in his career, he held several senior leadership positions at PHOENIX group SE, with responsibilities spanning strategic development, operational excellence and market expansion. As a board member of Tamro Baltics SIA, he oversaw pharmaceutical retail operations across Estonia, Latvia and Lithuania.

Dr. Schwesig began his career in international industrial research at the Bremen Institute for Production and Logistics. He holds a PhD in engineering from the University of Bremen and a degree in Industrial Engineering & Management. He has also completed executive education programmes at IMD Lausanne, Stanford Graduate School of Business, Cambridge University, IESE Business School and London Business School.

Dr. Martin Zügel has over 35 years of experience in executive positions in the healthcare industry, including more than 25 years of boardroom experience for global companies in both executive and non-executive roles.
Dr. Zügel served as Holding CEO of Klosterfrau Zürich AG, CEO of Merz Pharma KGaA and member of the executive board of B.Braun Melsungen AG. He was also chairman of the supervisory board for Glycotope and AMSilk GmbH and acted as senior health advisor for the private equity firm CVC Capital Partners.

Mr. Zügel is currently working as independent business consultant in Cologne, is Chairman of the Board AC Immune SA, Lausanne (CH), chairman of the supervisory board AMW GmbH, Warngau and MESI Ltd., Ljubljana (SLO).
Dr. Zügel holds a Doctorate degree in medicine from the University of Tübingen and a Master of Science in Molecular Biology from the University of Massachusetts, Amherst, United States.